Current News

Contact | Print version | PDF version | Send article | RSS feed

NasVax receives Ministry of Health Approval for a Phase 1/2a Clinical Study for Improved Flu Vaccine

17 Aug 2007 - NasVax Ltd., Israeli biotechnology company developing innovative biopharmaceutical products for improving immune responses and administration of vaccines, has announced that it received approval from the Helsinki Committee and the Israel Ministry of Health to perform a Phase 1/2a clinical study for its improved influenza vaccine, through the intramuscular route. The company initiated the clinical study in around 100 volunteers on July 11. This combination Phase 1/2a study addresses the safety and efficacy of the immune response to vaccination.
 
NasVax engages in the development of vaccines based on its technology platform for improving the immune response to vaccines and enabling both injection and intranasal administration. This technology utilizes CCS/C, a novel biocompatible adjuvant and delivery system, which has been shown to stimulate not only an increased antibody response but also produce a response in T-cells, hence further improved potency. This potent system opens the way for developing further product applications for preventing or treating both infectious and noninfectious diseases.
 
The company's adjuvant and delivery technology for improving vaccines is based on joint research by Professors Eli Kedar and Yechezkel Barenholz, co-inventor of a liposomal formulation of doxorubicin for cancer treatment, marketed in the USA by Johnson & Johnson (as DoxilTM) and in Europe by Schering Plough (as Caelyx).